US FDA withdraws 27 Ranbaxy ANDAs under consent decree
This article was originally published in Scrip
Executive Summary
As part of a consent decree of permanent injunction filed last January, the US FDA officially withdrew approval of 27 abbreviated new drug applications (ANDAs) held by Indian generic manufacturer Ranbaxy, the agency revealed on 21 August in a Federal Register notice.